| 2019-CHOP-68541 | |
| Researchers at Purdue University have developed pH-dependent fluorogenic amyloid-beta reporters for the study of Alzheimer's disease (AD). Microglial phagocytosis of amyloid-beta peptides is a critical step in the regulation of brain homeostasis during the initiation and progression of AD. Unlike common methods to study this phenomenon, this technology is specific for amyloid-beta and functions in live cells. The reporter, an isoform of human amyloid-beta tagged with a pH-dependent fluorogenic moiety, fluoresces only upon phagocytosis in the acidic intracellular phagosomes. It clearly differentiates between phagocytic and non-phagocytic cells within live human and nonhuman microglial cells. This technology promises to aid in the discovery of new therapeutics for AD. Advantages: -Facilitates live cell tracking of microglial phagocytosis -Differentiates between phagocytic and non-phagocytic microglial cells Potential Applications: -Development of Alzheimer's Therapeutics Publication: Monitoring phagocytic uptake of amyloid β into glial cell lysosomes in real time. doi: https://doi.org/10.1101/2020.03.29.002857 |
|
|
|
|
Sep 27, 2021
NATL-Patent
United States
(None)
(None)
Mar 27, 2020
PCT-Patent
WO
(None)
(None)
Mar 29, 2019
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
